Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart Transplantation.

J Am Heart Assoc · 2021 · PMC7955460 · PMID 33325244

Europe PMC DOI

hedged sentence

0.0400

closest p · 0.8× alpha

0.0400

boldest claim

The sentences

marginally significantP =0.04actually significant

A trend for increased percentage of fibrosis was seen in the sirolimus group (8.48±3.17 to 10.10±3.0%; P =0.07) as compared with marginally significant progression in the CNI group (8.76±3.87 to 10.56±4.34%; P =0.04).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.